Cargando…

N4-hydroxycytidine, the active compound of Molnupiravir, promotes SARS-CoV-2 mutagenesis and escape from a neutralizing nanobody

N4-hydroxycytidine (NHC), the active compound of the drug Molnupiravir, is incorporated into SARS-CoV-2 RNA, causing false base pairing. The desired result is an “error catastrophe,” but this bears the risk of mutated virus progeny. To address this experimentally, we propagated the initial SARS-CoV-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zibat, Arne, Zhang, Xiaoxiao, Dickmanns, Antje, Stegmann, Kim M., Dobbelstein, Adrian W., Alachram, Halima, Soliwoda, Rebecca, Salinas, Gabriela, Groß, Uwe, Görlich, Dirk, Kschischo, Maik, Wollnik, Bernd, Dobbelstein, Matthias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507161/ https://www.ncbi.nlm.nih.gov/pubmed/37731621 http://dx.doi.org/10.1016/j.isci.2023.107786

Ejemplares similares

Inhibitors of dihydroorotate dehydrogenase cooperate with molnupiravir and N4-hydroxycytidine to suppress SARS-CoV-2 replication
por: Stegmann, Kim M., et al.
Publicado: (2022)

Therapeutische Nanobodies gegen SARS-CoV-2
por: Güttler, Thomas, et al.
Publicado: (2022)

Neutralization of SARS‐CoV‐2 by highly potent, hyperthermostable, and mutation‐tolerant nanobodies
por: Güttler, Thomas, et al.
Publicado: (2021)

Could chlorophyllins improve the safety profile of beta-d-N4-hydroxycytidine versus N-hydroxycytidine, the active ingredient of the SARS-CoV-2 antiviral molnupiravir?
por: Clark, Nicole F., et al.
Publicado: (2022)

The folate antagonist methotrexate diminishes replication of the coronavirus SARS-CoV-2 and enhances the antiviral efficacy of remdesivir in cell culture models
por: Stegmann, Kim M., et al.
Publicado: (2021)

CDK4 inhibition diminishes p53 activation by MDM2 antagonists
por: Sriraman, Anusha, et al.
Publicado: (2018)

Oxidative DNA Damage by N(4)-hydroxycytidine, a Metabolite of the SARS-CoV-2 Antiviral Molnupiravir
por: Kobayashi, Hatasu, et al.
Publicado: (2022)

Transporter modulation of molnupiravir and its metabolite β-D-N4-hydroxycytidine across the blood-brain barrier in a rat
por: Chang, Chun-Hao, et al.
Publicado: (2023)

Transfer and biotransformation of the COVID-19 prodrug molnupiravir and its metabolite β-D-N4-hydroxycytidine across the blood-placenta barrier
por: Chang, Chun-Hao, et al.
Publicado: (2023)

CDK4/6 inhibition confers protection of normal gut epithelia against gemcitabine and the active metabolite of irinotecan
por: Blume, Joshua, et al.
Publicado: (2023)

Pharmacokinetics of ß-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection
por: FitzGerald, Richard, et al.
Publicado: (2022)

Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis
por: Kabinger, Florian, et al.
Publicado: (2021)

Decoding molnupiravir-induced mutagenesis in SARS-CoV-2
por: Menéndez-Arias, Luis
Publicado: (2021)

The development and validation of a novel LC-MS/MS method for the simultaneous quantification of Molnupiravir and its metabolite ß-d-N4-hydroxycytidine in human plasma and saliva
por: Amara, Alieu, et al.
Publicado: (2021)

β-d-N(4)-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells
por: Zhou, Shuntai, et al.
Publicado: (2021)

Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template
por: Gordon, Calvin J., et al.
Publicado: (2021)

MFmap: A semi-supervised generative model matching cell lines to tumours and cancer subtypes
por: Zhang, Xiaoxiao, et al.
Publicado: (2021)

Distinct and Common Features of Numerical and Structural Chromosomal Instability across Different Cancer Types
por: Zhang, Xiaoxiao, et al.
Publicado: (2022)

Interchanging heads: p53 re-composes the DREAM/MMB complex to repress transcription
por: Dobbelstein, Matthias
Publicado: (2013)

Development and Validation of a High-Performance Liquid Chromatography with Tandem Mass Spectrometry (HPLC-MS/MS) Method for Quantification of Major Molnupiravir Metabolite (β-D-N4-hydroxycytidine) in Human Plasma
por: Komarov, Timofey, et al.
Publicado: (2023)

Analysis of the Potential for N(4)-Hydroxycytidine To Inhibit Mitochondrial Replication and Function
por: Sticher, Zachary M., et al.
Publicado: (2020)

Development and validation of assays for the quantification of β-D-N(4)-hydroxycytidine in human plasma and β-D-N(4)-hydroxycytidine-triphosphate in peripheral blood mononuclear cell lysates
por: Parsons, Teresa L., et al.
Publicado: (2021)

Molnupiravir Does Not Induce Mutagenesis in Host Lung Cells during SARS-CoV-2 Treatment
por: Githaka, John Maringa
Publicado: (2022)

Mdm2: Open questions
por: Dobbelstein, Matthias, et al.
Publicado: (2020)

BRCA1 and Tip60 determine the cellular response to ultraviolet irradiation through distinct pathways
por: Kranz, Dominique, et al.
Publicado: (2008)

Wee1 is required to sustain ATR/Chk1 signaling upon replicative stress
por: Saini, Priyanka, et al.
Publicado: (2015)

Overcoming EMT-driven therapeutic resistance by BH3 mimetics
por: Keitel, Ulrike, et al.
Publicado: (2014)

Wee1 and Chk1 – crosstalk between key players in replicative stress
por: Saini, Priyanka, et al.
Publicado: (2015)

Fortifying p53 – beyond Mdm2 inhibitors
por: Sriraman, Anusha, et al.
Publicado: (2016)

Isolation of an escape-resistant SARS-CoV-2 neutralizing nanobody from a novel synthetic nanobody library
por: Dormeshkin, Dmitri, et al.
Publicado: (2022)

HSP90 inhibitor antagonizing MIF: The specifics of pleiotropic cancer drug candidates
por: Schulz, Ramona, et al.
Publicado: (2012)

G2E3 attenuating replicative stress
por: Schmidt, Franziska, et al.
Publicado: (2015)

Mdm2 as a chromatin modifier
por: Wienken, Magdalena, et al.
Publicado: (2017)

Reduced-intensity, risk factor–stratified immunosuppression for acquired hemophilia A: single-center observational study
por: Dobbelstein, Christiane, et al.
Publicado: (2020)

Molnupiravir: First Approval
por: Syed, Yahiya Y.
Publicado: (2022)

Computational Analysis of Molnupiravir
por: Sharov, Artem V., et al.
Publicado: (2022)

Molnupiravir for COVID-19
Publicado: (2022)

Mdm2 inhibition confers protection of p53-proficient cells from the cytotoxic effects of Wee1 inhibitors
por: Li, Yizhu, et al.
Publicado: (2015)

Facile isolation of high-affinity nanobodies from synthetic libraries using CDR-swapping mutagenesis
por: Zupancic, Jennifer M., et al.
Publicado: (2022)

Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape
por: Mast, Fred D, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_spjk2n8001eeafmie4vrr90dvq